PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations

Описание к видео PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations

Dr Hedy Kindler talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about results from the POLO trial looking at the use of the PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations

She explains that this trial is the first phase III trial showing that a targeted treatment in a biomarker selective group of pancreatic cancer patients can improve progression free survival.

Dr Kindler reports that patients who received olaparib had a median progression free survival of 7.4 months compared with 3.8 months for those who received the placebo.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.phps

Комментарии

Информация по комментариям в разработке

Похожие видео